These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12068840)

  • 1. Combined acellular pertussis vaccines: new indication. No tangible benefit in primary vaccination.
    Prescrire Int; 2002 Jun; 11(59):73-5. PubMed ID: 12068840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acellular pertussis vaccines: new preparation. Better tolerated but less active?
    Prescrire Int; 2000 Feb; 9(45):204-7. PubMed ID: 11503797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of recent clinical trials of acellular pertussis vaccines.
    Miller E
    Biologicals; 1999 Jun; 27(2):79-86. PubMed ID: 10600188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composition of acellular pertussis and combination vaccines: a general review.
    Jadhav SS; Gairola S
    Biologicals; 1999 Jun; 27(2):105-10. PubMed ID: 10600195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.
    David S; Vermeer-de Bondt PE; van der Maas NA
    Vaccine; 2008 Oct; 26(46):5883-7. PubMed ID: 18775463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6.
    Blennow M; Granström M; Olin P; Tiru M; Jäätmaa E; Askelöf P; Sato Y
    Dev Biol Stand; 1986; 65():185-90. PubMed ID: 3549397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccines: maybe slightly less effective, but better tolerated.
    Prescrire Int; 2000 Feb; 9(45):220-3. PubMed ID: 11503804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reflections on the effectiveness of the new combined vaccines].
    Bégué P
    Bull Acad Natl Med; 1998; 182(3):567-77; discussion 577-9. PubMed ID: 9673053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What uses for the acellular pertussis vaccine?].
    Grimprel E; Bégué P
    Arch Pediatr; 1998 May; 5(5):557-60. PubMed ID: 9759192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
    Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
    Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
    McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
    Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
    Geier DA; Geier MR
    Brain Dev; 2004 Aug; 26(5):296-300. PubMed ID: 15165669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of two pertussis vaccines in preterm Danish children.
    Hviid A
    Vaccine; 2009 May; 27(23):3035-8. PubMed ID: 19428916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
    Rieber N; Graf A; Belohradsky BH; Hartl D; Urschel S; Riffelmann M; Wirsing von König CH; Liese J
    Vaccine; 2008 Dec; 26(52):6929-35. PubMed ID: 18852002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.